MENLO PARK, Calif.–(BUSINESS WIRE)–Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced that company management will participate in two upcoming investor conferences in April.
Details of the events are as follows:
Canaccord Genuity 2022 Horizons in Oncology Virtual Conference, April 14, 2022
Chen Schor, President and Chief Executive Officer, will participate in a panel discussion titled, “Gamma Delta T-cells: A differentiated approach” on Thursday, April 14, 2022, at 12:00 PM ET.
2022 Jefferies Biotech on the Bay Summit, April 26-27, 2022
Adicet’s management team will participate in 1×1 investor meetings at the St. Regis, Bal Harbour in Miami, Florida on April 27, 2022.
About Adicet Bio, Inc.
Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with CAR and T cell receptor-like targeting moieties to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. For more information, please visit our website at http://www.adicetbio.com.
Contacts
Adicet Bio., Inc.
Investor and Media Contacts
Anne Bowdidge
abowdidge@adicetbio.com
Janhavi Mohite
Stern Investor Relations, Inc.
212-362-1200
janhavi.mohite@sternir.com
